These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 1547551)
1. Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism. Black IW; Wilcken DE Clin Chem; 1992 Mar; 38(3):353-7. PubMed ID: 1547551 [TBL] [Abstract][Full Text] [Related]
2. Plasma lipoprotein composition, apolipoprotein(a) concentration and isoforms in beta-thalassemia. Maioli M; Vigna GB; Tonolo G; Brizzi P; Ciccarese M; Donegà P; Maioli M; Fellin R Atherosclerosis; 1997 May; 131(1):127-33. PubMed ID: 9180253 [TBL] [Abstract][Full Text] [Related]
3. LDL-apheresis in patients with nephrotic syndrome: effects on serum albumin and urinary albumin excretion. Stenvinkel P; Alvestrand A; Angelin B; Eriksson M Eur J Clin Invest; 2000 Oct; 30(10):866-70. PubMed ID: 11029600 [TBL] [Abstract][Full Text] [Related]
4. Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome. de Zeeuw D; Gansevoort RT; Dullaart RP; de Jong PE J Hypertens Suppl; 1995 Jul; 13(1):S53-8. PubMed ID: 18800457 [TBL] [Abstract][Full Text] [Related]
5. Effects of short-term treatment with corticotropin on the serum apolipoprotein pattern. Arnadottir M; Dallongeville J; Nilsson-Ehle P; Berg AL Scand J Clin Lab Invest; 2001 Jul; 61(4):301-6. PubMed ID: 11465344 [TBL] [Abstract][Full Text] [Related]
6. Short-term effects of renal transplantation on plasma lipids and lipoprotein lipase in children with congenital nephrosis. Antikainen M; Holmberg C; Taskinen MR Clin Nephrol; 1994 May; 41(5):284-9. PubMed ID: 8050208 [TBL] [Abstract][Full Text] [Related]
7. Changes in serum lipoprotein(a) and lipids during treatment of hyperthyroidism. Kung AW; Pang RW; Lauder I; Lam KS; Janus ED Clin Chem; 1995 Feb; 41(2):226-31. PubMed ID: 7874776 [TBL] [Abstract][Full Text] [Related]
8. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. de Sain-van der Velden MG; Kaysen GA; Barrett HA; Stellaard F; Gadellaa MM; Voorbij HA; Reijngoud DJ; Rabelink TJ Kidney Int; 1998 Apr; 53(4):994-1001. PubMed ID: 9551409 [TBL] [Abstract][Full Text] [Related]
9. Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study. Granata A; Sobbrio GA; D'Arrigo F; Barillari M; Curasì MP; Egitto M; Trimarchi F; Granese D; Pullè C Acta Eur Fertil; 1990; 21(3):143-6. PubMed ID: 2149913 [TBL] [Abstract][Full Text] [Related]
10. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids. Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162 [TBL] [Abstract][Full Text] [Related]
12. Serum lipoproteins improve after successful pharmacologic antidepressant treatment: a randomized open-label prospective trial. Hummel J; Westphal S; Weber-Hamann B; Gilles M; Lederbogen F; Angermeier T; Luley C; Deuschle M; Kopf D J Clin Psychiatry; 2011 Jul; 72(7):885-91. PubMed ID: 21294998 [TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Attman PO; Samuelsson OG; Moberly J; Johansson AC; Ljungman S; Weiss LG; Knight-Gibson C; Alaupovic P Kidney Int; 1999 Apr; 55(4):1536-42. PubMed ID: 10201020 [TBL] [Abstract][Full Text] [Related]
14. Lipids, lipoproteins and apolipoproteins abnormalities in patients undergoing dialysis. Yang X; Wang H; Zhu Z; Deng A J Tongji Med Univ; 1997; 17(2):126-8. PubMed ID: 9639806 [TBL] [Abstract][Full Text] [Related]
15. Lipids in the progression of chronic renal failure. Cappelli P; Evangelista M; Bonomini M; Palmieri PF; Albertazzi A Nephron; 1992; 62(1):31-5. PubMed ID: 1436288 [TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. Ginsberg HN; Le NA; Goldberg IJ; Gibson JC; Rubinstein A; Wang-Iverson P; Norum R; Brown WV J Clin Invest; 1986 Nov; 78(5):1287-95. PubMed ID: 3095375 [TBL] [Abstract][Full Text] [Related]
17. Correlation of high density lipoprotein (HDL)-associated sphingosine 1-phosphate with serum levels of HDL-cholesterol and apolipoproteins. Zhang B; Tomura H; Kuwabara A; Kimura T; Miura S; Noda K; Okajima F; Saku K Atherosclerosis; 2005 Jan; 178(1):199-205. PubMed ID: 15585219 [TBL] [Abstract][Full Text] [Related]
18. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes. Berneis K; Jeanneret C; Muser J; Felix B; Miserez AR Metabolism; 2005 Feb; 54(2):227-34. PubMed ID: 15690318 [TBL] [Abstract][Full Text] [Related]
19. Measurement of plasma small-dense LDL concentration by a simplified ultracentrifugation procedure and immunoassay of apolipoprotein B. Menys VC; Liu Y; Mackness MI; Caslake MJ; Kwok S; Durrington PN Clin Chim Acta; 2003 Aug; 334(1-2):95-106. PubMed ID: 12867279 [TBL] [Abstract][Full Text] [Related]
20. Small dense low-density lipoprotein in renal transplant recipients: a potential target for prevention of cardiovascular complications? Badiou S; Garrigue V; Dupuy AM; Chong G; Cristol JP; Mourad G Transplant Proc; 2006 Sep; 38(7):2314-6. PubMed ID: 16980076 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]